Opioid Peptides Protect Heart Cells From Death Through Delta and Kappa Receptors via KATP Channels | Research

The takeaway

Delta-opioid (met-enkephalin) and kappa-opioid (dynorphin A) receptor activation protected isolated heart cells from simulated ischemia through KATP channel opening — the same protective mechanism as ischemic preconditioning.

Two opioid receptors protect
Both delta (enkephalin) and kappa (dynorphin) activation protected heart cells through KATP channels — the same mechanism as ischemic preconditioning

What the researchers found

Delta-opioid (met-enkephalin) and kappa-opioid (dynorphin A) receptor activation protected cardiomyocytes from simulated ischemia through KATP channel opening, confirming the opioid-KATP cardioprotection pathway.

Why it matters

Understanding exactly how opioid peptides protect the heart enables development of cardiac-specific opioid drugs that prevent heart attack damage without affecting the brain.

How the study worked

In-vitro study using freshly isolated adult rabbit cardiomyocytes. Simulated ischemia with selective opioid agonists, receptor antagonists, and KATP channel blockers to dissect the protective mechanism.

What this study cannot tell us

Isolated cell model. Cardiomyocyte protection in vitro may not predict whole-heart or in-vivo protection. The interaction between delta and kappa pathways was not fully explored.

How to read the evidence

Preliminary in-vitro evidence with clear receptor and channel specificity from selective pharmacological blocking in isolated cardiomyocytes.

When this study was published

Published in 2003. The opioid-KATP cardiac protection pathway has been confirmed and is a recognized cardioprotective mechanism.

The bigger picture

The heart has its own opioid protection system that mimics ischemic preconditioning. This natural defense can be pharmacologically enhanced to prevent heart attack damage — a major therapeutic opportunity.

Questions still open

Could cardiac-selective delta/kappa agonists prevent infarction?
Does the protection work post-ischemia (post-conditioning) as well as pre-ischemia?
Do patients on glibenclamide (diabetics) lose this cardiac opioid protection?

Common questions

Does the heart protect itself with opioids?

Yes. The heart has opioid receptors (delta and kappa) that, when activated by natural opioid peptides, open protective KATP channels. This is the same mechanism as ischemic preconditioning — the heart's built-in defense.

Could diabetics on glibenclamide be at risk?

Potentially — glibenclamide blocks KATP channels. This study shows the opioid heart protection requires KATP channels. Diabetics on glibenclamide might lose this natural cardiac defense, which has clinical implications.

Read the original research

Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.

American journal of physiology. Heart and circulatory physiology, 285(3), H1032-9

View on PubMed ↗

Citation

Cao, Zhiping; Liu, Lijuan; Van Winkle, Donna M. (2003). Activation of delta- and kappa-opioid receptors by opioid peptides protects cardiomyocytes via KATP channels.. American journal of physiology. Heart and circulatory physiology, 285(3), H1032-9.